CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M J. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001; 61: 5137–5144
   PubMed Web of Science ®Google Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–186
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, Bassan R, Rambaldi A, Golay J. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800–809
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-Lopez A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• Vose J M, Link B K, Grossbard M L, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Haberman T, Weller E, Morrison V, Gascoyne R, Cassileth P, Cohn J, et al. Phase II trial of rituximab-CHOP vs. CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B-cell lymphoma. Blood 2003; 102: 6a
   Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Ma D, Osterborg A, Pettengell R, Treneny M, et al. Randomised inter-group trial of first-line treatment of patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma with a CHOP-like regimen with or without the anti-CD20 antibody rituximab—early stopping after the first interim analysis. Proceedings of the American Association for Cancer Research. 2004, 556a
   Google Scholar
• Davis T A, Grillo-Lopez A J, White C A, McLaughlin P, Czuczman M S, Link B K, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–3143
   PubMed Web of Science ®Google Scholar
• Smith M R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359–7368
   PubMed Web of Science ®Google Scholar
• Clynes R A, Towers T L, Presta L G, Ravetch J V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443–446
   PubMed Web of Science ®Google Scholar
• Koene H R, Kleijer M, Algra J, Roos D, von dem Borne A E, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109–1114
   PubMed Web of Science ®Google Scholar
• Wu J, Edberg J C, Redecha P B, Bansal V, Guyre P M, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059–1070
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754–758
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G M, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908
   PubMed Web of Science ®Google Scholar
• Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634–641
   PubMed Web of Science ®Google Scholar
• Treon S P, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother (1997) 2001; 24: 263–271
   PubMed Web of Science ®Google Scholar
• Davis T A, Czerwinski D K, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611–615
   PubMed Web of Science ®Google Scholar
• Kennedy G A, Tey S K, Cobcroft R, Marlton P, Cull G, Grimmett K, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol 2002; 119: 412–416
   PubMed Web of Science ®Google Scholar
• Chu P G, Chen Y Y, Molina A, Arber D A, Weiss L M. Recurrent B-cell neoplasms after rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma 2002; 43: 2335–2341
   PubMed Web of Science ®Google Scholar
• Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, Bosch-Princep R, Salvado-Usach M T. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol 2003; 82: 585–588
   PubMed Web of Science ®Google Scholar
• Czuczman M, Bdair F, Gowda A, Brombos D, Hernandez F. Development of rituximab resistance is associated with structural changes of the internal domain of CD20 antigen in non-Hodgkin's lymphoma cell lines. Proceedings of the American Association for Cancer Research. 2004, 45
   Google Scholar
• Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 2006; 30: 625–631
   PubMed Web of Science ®Google Scholar
• Czuczman M, Olejniczak S, Gowda A, Starostik P, Hernandez F. Acquirement of rituximab resistance in lymphoma cell lines is associated with structural changes in the internal domain of CD20 regulated at the post-transcriptional level. Blood (Suppl.) 2004; 104: 2280
   Web of Science ®Google Scholar
• Olejniczak S, Hernandez F, Clements J, Czuczman M. Loss of expression of the pro-apoptotic Bcl-2 family proteins Bak and Bax in rituximab and chemotherapy resistant non-Hodgkin's cell lines. Blood (Suppl.) 2005; 106: 4819
   Web of Science ®Google Scholar
• Hernandez F, Kaur H, Bhinder A, Olejniczak S, Knight J, Czuczman M. Impaired Ca++ mobilization in RRCL is associated with changes in the structure of CD20 antigen, down-regulation of Bax/Bak pro-apoptotic proteins and up-regulation of the endoplasmic reticulum Ca++ pump protein SERCA-3. Proc ASCO 2006; 34: 2516
   Google Scholar
• Olejniczak S, Clements J, Hernandez F, Bangia N, Czuczman M. Post-transcriptional regulation of Bax and Bak protein expression in rituximab and chemotherapy resistant B-cell non-Hodgkin's lymphoma cells. Proceedings of the American Association for Cancer Research. 2006, 47
   Google Scholar
• Polyak M J, Ayer L M, Szczepek A J, Deans J P. A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia 2003; 17: 1384–1389
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98: 3383–3389
   PubMed Web of Science ®Google Scholar
• Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. Eur J Immunol 2005; 35: 2175–2183
   PubMed Web of Science ®Google Scholar
• Nagajothi N, Matsui W H, Mukhina G L, Brodsky R A. Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins. Leuk Lymphoma 2004; 45: 795–799
   PubMed Web of Science ®Google Scholar
• Terui Y, Sakurai T, Mishima Y, Sugimura N, Sasaoka C, Kojima K, et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 2006; 97: 72–79
   PubMed Web of Science ®Google Scholar
• Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999; 20: 576–582
   PubMedGoogle Scholar
• Brasoveanu L I, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra M R, et al. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest 1996; 74: 33–42
   Google Scholar
• Gorter A, Blok V T, Haasnoot W H, Ensink N G, Daha M R, Fleuren G J. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest 1996; 74: 1039–1049
   PubMed Web of Science ®Google Scholar
• Jarvis G A, Li J, Hakulinen J, Brady K A, Nordling S, Dahiya R, et al. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 1997; 71: 1049–1055
   PubMed Web of Science ®Google Scholar
• Cheung N K, Walter E I, Smith-Mensah W H, Ratnoff W D, Tykocinski M L, Medof M E. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 1988; 81: 1122–1128
   PubMed Web of Science ®Google Scholar
• Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement-regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70: 14–25
   PubMed Web of Science ®Google Scholar
• Maenpaa A, Junnikkala S, Hakulinen J, Timonen T, Meri S. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol 1996; 148: 1139–1152
   PubMed Web of Science ®Google Scholar
• Weng W K, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001; 98: 1352–1357
   PubMed Web of Science ®Google Scholar
• Junnikkala S, Hakulinen J, Meri S. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol 1994; 24: 611–615
   PubMed Web of Science ®Google Scholar
• Harris C L, Kan K S, Stevenson G T, Morgan B P. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin Exp Immunol 1997; 107: 364–371
   PubMed Web of Science ®Google Scholar
• Blok V T, Daha M R, Tijsma O, Harris C L, Morgan B P, Fleuren G J, et al. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998; 160: 3437–3443
   PubMed Web of Science ®Google Scholar
• Gall J M, Davol P A, Grabert R C, Deaver M, Lum L G. T cells armed with anti-CD3×anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 2005; 33: 452–459
   PubMed Web of Science ®Google Scholar
• Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 1994; 73: 2808–2817
   PubMed Web of Science ®Google Scholar
• Gelderman K A, Blok V T, Fleuren G J, Gorter A. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies. Lab Invest 2002; 82: 483–493
   PubMed Web of Science ®Google Scholar
• Rowan W C, Hale G, Tite J P, Brett S J. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995; 7: 69–77
   PubMed Web of Science ®Google Scholar
• Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119(Part 1)225–237
   PubMed Web of Science ®Google Scholar
• Hederer R A, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, et al. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol 2000; 12: 505–516
   PubMed Web of Science ®Google Scholar
• Huh Y, Kantarjian H, Pierce S, Buesco-Ramos C, Hirsch-Ginsberg C, Albitar M. Expression of CD52 in human hematopoietic malignancies. Blood (Suppl.) 1998; 92: 4199
   Google Scholar
• Rowan W, Tite J, Topley P, Brett S J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998; 95: 427–436
   PubMed Web of Science ®Google Scholar
• Salisbury J R, Rapson N T, Codd J D, Rogers M V, Nethersell A B. Immunohistochemical analysis of CDW52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994; 47: 313–317
   PubMed Web of Science ®Google Scholar
• Bass A J, Gong J, Nelson R, Rizzieri D A. CD52 expression in mantle cell lymphoma. Leuk Lymphoma 2002; 43: 339–342
   PubMed Web of Science ®Google Scholar
• Elsner J, Hochstetter R, Spiekermann K, Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996; 88: 4684–4693
   PubMed Web of Science ®Google Scholar
• Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137–143
   PubMed Web of Science ®Google Scholar